GPC starts Phase II trial for lung cancer
GPC Biotech said on Wednesday it had started a Phase II trial to evaluate its lead drug, satraplatin, in combination with Tarceva to treat patients with advanced non-small cell lung cancer who cannot undergo surgery and are 70 years or older.
This entry was posted on Friday, August 4th, 2006 at 8:03 am and is filed under Research, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.